Krystal Biotech, Inc. (KRYS)
|52 Week Range||49.17-128.6|
|1y Target Est||-|
|DCF Unlevered||KRYS DCF ->|
|DCF Levered||KRYS LDCF ->|
|Debt / Equity||6.94%||Neutral|
Upgrades & Downgrades
Latest KRYS news
Up 48% in 2023, Is This Biotech Stock a Buy?
3 June 2023
Krystal Biotech recently reached an important milestone with the approval of its lead candidate Vyjuvek. Although this product represents a breakthrough, the overall market opportunity is not massive.
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
30 May 2023
Last week, shares of the Pittsburgh-based genetic medicines developer surged more than 25% after the FDA approved its therapy for a rare skin disease called dystrophic epidermolysis bullosa, or DEB. A...
Why Shares of Krystal Biotech Are Rising Monday
22 May 2023
Krystal Biotech announced on Friday that Vyjuvek had been approved by the FDA to treat a rare skin disorder. The company said it plans to launch the gene therapy by the third quarter.
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
22 May 2023
Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.
Krystal Biotech stock rises after FDA approves treatment for rare skin disease
19 May 2023
Krystal Biotech Inc. KRYS, +5.49% shares rose Friday after the biotech drug company received Food and Drug Administration approval of a rare skin disease treatment. Krystal shares rose as much as 8% t...
U.S. FDA approves Krystal Biotech's skin disorder gene therapy
19 May 2023
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's topical gene therapy for patients with a genetic skin disorder, making it the first-of-its kind treatment for epidermolys...
Krystal Biotech: 2 Potential Regulatory Approvals To Carry It Forward
8 May 2023
Krystal Biotech, Inc. has a PDUFA date of May 19, 2023, established for the FDA to review B-VEC for potential U.S. marketing approval to treat patients with Dystrophic Epidermolysis Bullosa. There is ...
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
13 April 2023
Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute
Krystal Biotech: Reached My Price Target, Waiting For A Drop
20 January 2023
I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >